{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:14:22Z","timestamp":1778742862755,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018430","name":"Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018430","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","award":["Ain Shams University Strategic Research Grant"],"award-info":[{"award-number":["Ain Shams University Strategic Research Grant"]}],"id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lysine specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent histone demethylase which is overexpressed in acute myeloid leukemias (AMLs). Indeed, several selective LSD1 inhibitors (LSD1is) are currently evaluated in clinical trials. We previously demonstrated that the mammalian target of rapamycin (mTOR) signalling is inhibited in LSD1i-sensitive AMLs and is activated in LSD1i-partially responsive\/tolerant AMLs following LSD1i. Herein, we sought to systematically decipher the molecular basis underlying the responsiveness of AML cells to LSD1is. Genome-wide transcriptomic profiling, RT-qPCR and immunoblot analyses revealed that stem cell factor tyrosine kinase receptor (KIT) is preferentially overexpressed in LSD1i-sensitive AMLs compared to LSD1i-partially responsive\/tolerant AMLs. Pharmacological and genetic interference with LSD1 repressed KIT transcription. c-Kit acted upstream of ERK\/mTOR signalling. Chromatin immunoprecipitation studies revealed that LSD1 binds in proximity to KIT TSS and modulates repressive H3K9me2 marks. Inhibiting c-Kit augmented the anti-leukemic activity of LSD1is in KIT-dependent AML cells. Consistently, KIT mRNA positively correlated with LSD1 transcript levels in primary human AML biospecimens and pharmacological LSD1i repressed KIT transcription in primary human AML samples\n                    <jats:italic>ex vivo<\/jats:italic>\n                    . Collectively, this study sheds light on the epigenetic modulation of KIT transcription by LSD1 and underscores the therapeutic potential of co-targeting LSD1\/KIT in KIT-dependent AMLs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13148-026-02098-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:04:27Z","timestamp":1778724267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibition"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-1183","authenticated-orcid":false,"given":"Amal Kamal","family":"Abdel-Aziz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-0975","authenticated-orcid":false,"given":"Mona Kamal","family":"Saadeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2098_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P, et al. Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1. Cell. 2004;119:941\u201353.","journal-title":"Cell"},{"key":"2098_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Setzger","year":"2005","unstructured":"Setzger E, Wissmann M, Yin N, M\u00fcller J, Schneider R, Peters A, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437:436\u20139.","journal-title":"Nature"},{"key":"2098_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3324\/haematol.2019.224501","volume":"105","author":"AK Abdel-Aziz","year":"2020","unstructured":"Abdel-Aziz AK, Pallavicini I, Ceccacci E, Meroni G, Saadeldin MK, Varasi M, et al. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition. Haematologica. 2020;105:2105\u2013211.","journal-title":"Haematologica"},{"key":"2098_CR4","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK, Minucci S. Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays. Pharmacol Res. 2019;104345.","DOI":"10.1016\/j.phrs.2019.104345"},{"key":"2098_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature06092","volume":"449","author":"J Huang","year":"2007","unstructured":"Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et al. p53 is regulated by the lysine demethylase LSD1. Nature. 2007;449:105\u20139.","journal-title":"Nature"},{"key":"2098_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5483\/BMBRep.2016.49.5.053","volume":"49","author":"SH Baek","year":"2016","unstructured":"Baek SH, Kim K, Il. Regulation of HIF-1 alpha stability by lysine methylation. BMB Rep. 2016;49:245\u20136.","journal-title":"BMB Rep"},{"key":"2098_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nn.4069","volume":"18","author":"J Wang","year":"2015","unstructured":"Wang J, Telese F, Tan Y, Li W, Jin C, He X, et al. LSD1n is an H4K20 demethylase regulating memory formation via transcriptional elongation control. Nat Neurosci. 2015;18:1256\u201364.","journal-title":"Nat Neurosci"},{"key":"2098_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","volume":"52","author":"S Gao","year":"2021","unstructured":"Gao S, Chen S, Han D, Wang Z, Li M, Han W, et al. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2021;52:1011\u20137.","journal-title":"Nat Genet"},{"key":"2098_CR9","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","volume":"22","author":"A Maiques-Diaz","year":"2018","unstructured":"Maiques-Diaz A, Spencer GJ, Lynch JT, Ciceri F, Williams EL, Amaral FMR, et al. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Rep. 2018;22:3641\u201359.","journal-title":"Cell Rep"},{"key":"2098_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.aax2746","volume":"6","author":"R Ravasio","year":"2020","unstructured":"Ravasio R, Ceccacci E, Nicosia L, Hosseini A, Rossi PL, Barozzi I, et al. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation. Sci Adv. 2020;6:1\u201313.","journal-title":"Sci Adv"},{"key":"2098_CR11","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1182\/blood-2014-11-610907","volume":"125","author":"T Wada","year":"2015","unstructured":"Wada T, Koyama D, Kikuchi J, Honda H, Furukawa Y. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood. 2015;125:3731\u201345.","journal-title":"Blood"},{"key":"2098_CR12","first-page":"2","volume":"5","author":"S Hodges","year":"2022","unstructured":"Hodges S, Cooney J. Novel lysine-specific histone demethylase 1 inhibitor in acute myeloid leukaemia transformed from essential thrombocythaemia. Cancer Rep. 2022;5:2\u20135.","journal-title":"Cancer Rep"},{"key":"2098_CR13","doi-asserted-by":"publisher","first-page":"115709","DOI":"10.1016\/j.bcp.2023.115709","volume":"215","author":"AK Abdel-Aziz","year":"2023","unstructured":"Abdel-Aziz AK. Advances in acute myeloid leukemia differentiation therapy: A critical review. Biochem Pharmacol. 2023;215:115709.","journal-title":"Biochem Pharmacol"},{"key":"2098_CR14","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.19.03250","volume":"38","author":"O Salamero","year":"2020","unstructured":"Salamero O, Montesinos P, Willekens C, P\u00e9rez-Sim\u00f3n JA, Pigneux A, R\u00e9cher C, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020;38:4260\u201373.","journal-title":"J Clin Oncol"},{"key":"2098_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","volume":"35","author":"M Wass","year":"2021","unstructured":"Wass M, G\u00f6llner S, Besenbeck B, Schlenk RF, Mundmann P, G\u00f6thert JR, et al. A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy. Leukemia. 2021;35:701\u201311.","journal-title":"Leukemia"},{"key":"2098_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2217\/epi-2016-0009","volume":"8","author":"A Maiques-Diaz","year":"2016","unstructured":"Maiques-Diaz A, Somervaille TCP. LSD1: Biologic roles and therapeutic targeting. Epigenomics. 2016;8:1103\u201316.","journal-title":"Epigenomics"},{"key":"2098_CR17","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1158\/0008-5472.CAN-15-2333","volume":"76","author":"JP McGrath","year":"2016","unstructured":"McGrath JP, Williamson KE, Balasubramanian S, Odate S, Arora S, Hatton C, et al. Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes. Cancer Res. 2016;76:1975\u201388.","journal-title":"Cancer Res"},{"key":"2098_CR18","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3324\/haematol.2018.199190","volume":"1","author":"KN Smitheman","year":"2019","unstructured":"Smitheman KN, Severson TM, Rajapurkar SR, Mccabe MT, Karpinich N, Foley J, et al. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-retinoic acid in acute myeloid leukemia across subtypes. Haematologica. 2019;1:1156\u201367.","journal-title":"Haematologica"},{"key":"2098_CR19","doi-asserted-by":"publisher","first-page":"85085","DOI":"10.18632\/oncotarget.18564","volume":"8","author":"J Fang","year":"2017","unstructured":"Fang J, Ying H, Mao T, Fang Y, Lu Y, Wang H, et al. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. Oncotarget. 2017;8:85085\u2013101.","journal-title":"Oncotarget"},{"key":"2098_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ab.2013.07.032","volume":"442","author":"JT Lynch","year":"2013","unstructured":"Lynch JT, Cockerill MJ, Hitchin JR, Wiseman DH, Somervaille TCP. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase. Anal Biochem. 2013;442:104\u20136.","journal-title":"Anal Biochem"},{"key":"2098_CR21","doi-asserted-by":"crossref","unstructured":"Deb G, Wingelhofer B, Amaral FMR, John AM, Spencer GJ, Williams EL et al. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia. Leukemia. 2019.","DOI":"10.1038\/s41375-019-0659-6"},{"key":"2098_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1021\/acs.jmedchem.5b01209","volume":"59","author":"P Vianello","year":"2016","unstructured":"Vianello P, Botrugno OA, Cappa A, Dal R, Dessanti P, Mai A, et al. Discovery of a Novel Inhibitor of Histone Lysine-Speci fi c Demethylase 1A (KDM1A\/LSD1) as Orally Active Antitumor Agent. J Med Chem. 2016;59:1501\u201317.","journal-title":"J Med Chem"},{"key":"2098_CR23","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK, Dokla EME, Abouzid KAM, Minucci S. Discovery of EMD37, a 1,2,4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity. Biochem Pharmacol. 2022;115316.","DOI":"10.1016\/j.bcp.2022.115316"},{"key":"2098_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"M Love","year":"2014","unstructured":"Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2098_CR25","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2019","unstructured":"Zhu A, Ibrahim J, Love M. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 2019;35:2084\u201392.","journal-title":"Bioinformatics"},{"key":"2098_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/bioinformatics\/btad018","volume":"39","author":"S L\u2019Yi","year":"2023","unstructured":"L\u2019Yi S, Keller MS, Dandawate A, Taing L, Chen CH, Brown M, et al. Cistrome Explorer: an interactive visual analysis tool for large-scale epigenomic data. Bioinformatics. 2023;39:2\u20133.","journal-title":"Bioinformatics"},{"key":"2098_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25:59\u201373.","journal-title":"Nat Rev Cancer"},{"key":"2098_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1210\/jc.2011-3269","volume":"97","author":"A Piscazzi","year":"2012","unstructured":"Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AMT, Antonetti R, et al. Activation of the RAS\/RAF\/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012;97:898\u2013906.","journal-title":"J Clin Endocrinol Metab"},{"key":"2098_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bcpt.12281","volume":"116","author":"AK Abdel-aziz","year":"2015","unstructured":"Abdel-aziz AK, Saad S, Azab E, Youssef SS, El-sayed AM, El-demerdash E. Modulation of Imatinib Cytotoxicity by Selenite in HCT116 Colorectal Cancer Cells. Basic Clin Pharmacol Toxicol. 2015;116:37\u201346.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2098_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11899-006-0020-9","volume":"1","author":"AS Advani","year":"2006","unstructured":"Advani AS. Targeting the c-kit receptor in the treatment of acute myelogenous leukemia. Curr Hematol Malig Rep. 2006;1:101\u20137.","journal-title":"Curr Hematol Malig Rep"},{"key":"2098_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, Iii ERM, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"2098_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow DP, Szpyt J, Ghandi M, Garraway LA, Sellers WR, Gygi SP. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 2020;180:387\u2013402.","journal-title":"Cell"},{"key":"2098_CR33","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41375-022-01594-1","volume":"36","author":"BM Curtiss","year":"2022","unstructured":"Curtiss BM, VanCampen J, Macaraeg J, Kong GL, Taherinasab A, Tsuchiya M, et al. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia. 2022;36:1781\u201393.","journal-title":"Leukemia"},{"key":"2098_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature10805","volume":"482","author":"WA Whyte","year":"2012","unstructured":"Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature. 2012;482:221\u20135.","journal-title":"Nature"},{"key":"2098_CR35","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1073\/pnas.1614664114","volume":"114","author":"J Carnesecchi","year":"2017","unstructured":"Carnesecchi J, Forcet C, Zhang L, Tribollet V, Barenton B, Boudra R, et al. ERR\u03b1 induces H3K9 demethylation by LSD1 to promote cell invasion. Proc Natl Acad Sci U S A. 2017;114:3909\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2098_CR36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"2098_CR37","doi-asserted-by":"crossref","unstructured":"Goda RY, Abdel-Aziz AK. Exploiting artificial intelligence in precision oncology: an updated comprehensive review. J Transl Med. 2025;2.","DOI":"10.1186\/s12967-025-07308-2"},{"key":"2098_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-019-0426-3","volume":"17","author":"Y Obata","year":"2019","unstructured":"Obata Y, Hara Y, Shiina I, Murata T, Tasaki Y, Suzuki K, et al. N822K-or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells. Cell Commun Signal. 2019;17:1\u201315.","journal-title":"Cell Commun Signal"},{"key":"2098_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2024.116255","volume":"268","author":"SWA Helmy","year":"2024","unstructured":"Helmy SWA, Abdel-Aziz AK, Dokla EME, Ahmed TE, Hatem Y, Abdel Rahman EA, et al. Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells. Eur J Med Chem. 2024;268:1\u201318.","journal-title":"Eur J Med Chem"},{"key":"2098_CR40","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK. OXPHOS mediators in acute myeloid leukemia patients: Prognostic biomarkers and therapeutic targets for personalized medicine. World J Surg Oncol. 2024;22.","DOI":"10.1186\/s12957-024-03581-5"},{"key":"2098_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1158\/1541-7786.MCR-22-0745","volume":"21","author":"WM Yashar","year":"2024","unstructured":"Yashar WM, Curtiss BM, Coleman DJ, Vancampen J, Kong G, Macaraeg J, et al. Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Mol Cancer Res. 2024;21:631\u201347.","journal-title":"Mol Cancer Res"},{"key":"2098_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010031","volume":"6","author":"BM Foster","year":"2018","unstructured":"Foster BM, Zaidi D, Young TR, Mobley ME, Kerr BA. CD117\/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines. 2018;6:1\u201319.","journal-title":"Biomedicines"},{"key":"2098_CR43","doi-asserted-by":"crossref","unstructured":"Mazzoldi EL, Pavan S, Pilotto G, Leone K, Pagotto A, Frezzini S et al. A juxtacrine\/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer. Cell Death Dis. 2019;10.","DOI":"10.1038\/s41419-019-1656-4"},{"key":"2098_CR44","first-page":"4879","volume":"62","author":"S Attoub","year":"2002","unstructured":"Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andr\u00e9 T, Mareel M, Mester JGC. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002;62:4879\u201383.","journal-title":"Cancer Res"},{"key":"2098_CR45","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhao L, Wu C, Liu P, Shi L, Liang Y et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. 2011;108:8\u201313.","DOI":"10.1073\/pnas.1019625108"},{"key":"2098_CR46","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1158\/0008-5472.CAN-11-0896","volume":"71","author":"J Wang","year":"2011","unstructured":"Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, Liu Y, Ward D, Quan J, Ye TZH. Novel Histone Demethylase LSD1 Inhibitors Selectively Target Cancer Cells with Pluripotent Stem Cell Properties. Cancer Res. 2011;71:7238\u201349.","journal-title":"Cancer Res"},{"key":"2098_CR47","doi-asserted-by":"crossref","unstructured":"Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T et al. Superior ef fi cacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021.","DOI":"10.1038\/s41408-021-00487-3"},{"key":"2098_CR48","doi-asserted-by":"publisher","first-page":"117114","DOI":"10.1016\/j.lfs.2019.117114","volume":"241","author":"HS Zhang","year":"2020","unstructured":"Zhang HS, Liu HY, Zhou Z, Sun HL, Liu MY. TSPAN8 promotes colorectal cancer cell growth and migration in LSD1-dependent manner. Life Sci. 2020;241:117114.","journal-title":"Life Sci"},{"key":"2098_CR49","doi-asserted-by":"crossref","unstructured":"Kerenyi MA, Shao Z, Hsu YJ, Guo G, Luc S, O\u2019Brien K et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife. 2013;1\u201323.","DOI":"10.7554\/eLife.00633.024"},{"key":"2098_CR50","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1182\/blood.V122.21.1448.1448","volume":"122","author":"H-J Tsai","year":"2013","unstructured":"Tsai H-J, Hsu T-AJ, Chen C-T, Jiang W-T. Hui-You Lin S-FL and L-TC. 1J373 Is a Promising Agent Against C-KIT driven Acute Myeloid Leukemia. Blood. 2013;122:1448.","journal-title":"Blood"},{"key":"2098_CR51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/leu.2012.7","volume":"26","author":"H Makishima","year":"2012","unstructured":"Makishima H, Sugimoto Y, Szpurka H, Clemente MJ, Ng KP, Muramatsu H, et al. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. Leukemia. 2012;26:1547\u201354.","journal-title":"Leukemia"},{"key":"2098_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1042\/BJ20060464","volume":"67","author":"K Masson","year":"2006","unstructured":"Masson K, Heiss E, Band H, Onnstrand LR. Direct binding of Cbl to Tyr 568 and Tyr 936 of the stem cell factor receptor\/c-Kit is required for ligand-induced ubiquitination, internalization. Biochem J. 2006;67:59\u201367.","journal-title":"Biochem J"},{"key":"2098_CR53","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.18632\/oncotarget.1202","volume":"4","author":"H Siemens","year":"2013","unstructured":"Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013;4:1399\u2013415.","journal-title":"Oncotarget"},{"key":"2098_CR54","doi-asserted-by":"publisher","first-page":"104139","DOI":"10.1016\/j.critrevonc.2023.104139","volume":"191","author":"AK Abdel-Aziz","year":"2023","unstructured":"Abdel-Aziz AK, Dokla EME, Saadeldin MK. FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review. Crit Rev Oncol Hematol. 2023;191:104139.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02098-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:02:39Z","timestamp":1778742159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02098-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02098-w","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}